Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Genius Group responds to abnormal stock fluctuations: reserves the right to hold accountable for any illegal or manipulative actions

Genius Group responds to abnormal stock fluctuations: reserves the right to hold accountable for any illegal or manipulative actions

Odaily星球日报Odaily星球日报2026/05/30 08:23
Show original

According to Odaily, US-listed Bitcoin treasury company Genius Group responded to NYSE American’s request for clarification on unusual market trading of its shares. Reportedly, the company’s stock price surged from $0.24 to $0.52 on May 27, a maximum intraday increase of 116%.

Genius Group stated that there have been no undisclosed significant developments in its business or operations. Previously, it disclosed that the board had approved an AI treasury strategy, with plans to invest up to $100 million in the AGI Infinity portfolio involving SpaceX, OpenAI, and others. In addition, its first round of Bitcoin shareholder rewards has ended, and the second round will launch on June 1. The company has also requested US market monitoring company Shareholder Intelligence to conduct a special analysis of market trading while reserving the right to pursue legal action against any illegal or manipulative behavior. (Globenewswire)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma

GlaxoSmithKline announced on Tuesday that it has reached an agreement with Chinese biotechnology company ImmuneOnco to acquire the global rights to one of the latter’s trispecific T-cell engagers (TCE) for a total transaction amount of up to $750 million.

智通财经2026/09/15 08:06
GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma